Anaemia, hypoproteinaemia and acidic pH in renal failure patients can alter the pharmacokinetics and pharmacodynamics of anaesthetic agents, resulting in altered dose requirements. We evaluated the induction dose of propofol in adult patients with end-stage renal disease by titrating the hypnotic effect by means of a clinical parameter as well as using a more objective assessment of hypnosis, the Bispectral Index (BIS) monitor. The dose was compared with that for patients with normal renal function. Propofol doses that provided the clinical end-point of hypnosis (syringe drop method), as well as the end-point of a mean (SD) BIS value of 50 (5), were evaluated in 27 end-stage renal disease and 27 normal renal function patients. Propofol was administered at 0.2mg/kg every 15 seconds until these end-points were achieved. End-stage renal disease patients required significantly higher propofol doses to achieve the clinical end-point of hypnosis (1.42 (0.24) mg/kg versus 0.89 (0.2) mg/kg in normal renal function patients, P<0.05 unpaired "t" test). Propofol dose required to achieve a BIS of 50 (5) was also higher in end-stage renal disease patients (2.03 (0.4) mg/kg versus 1.39 (0.43) mg/kg in normal renal function patients, P<0.05). There was a significant negative correlation of propofol dose with preoperative haemoglobin concentration. A hyperdynamic circulation in renal failure patients with anaemia may be responsible for the higher propofol dose requirement in this group.
Propofol has been used for induction and maintenance of anaesthesia among patients with end-stage renal disease and its safety in these patients is well established [1] [2] [3] . Anaemia, hypoproteinaemia, acidic pH, altered fluid distribution in various body compartments, altered drug binding with albumin and impaired hepatic metabolism in uraemia can alter the pharmacokinetics and pharmacodynamics of anaesthetic drugs 4, 5 , leading to over-or under-dosage.
Studies to date in end-stage renal disease patients have evaluated the profile of propofol that achieves certain pre-defined plasma concentrations by means of a target-controlled infusion 6 . They have not evaluated the dose requirement to achieve a particular level of hypnosis, which is the ultimate goal of anaesthetic practice. A drawback with fixed plasma concentration is that it may not provide a particular level of sedation and hypnosis for all patients, because of variability in inter-patient pharmacodynamics 7 .
The Bispectral index (BIS) is a processed electroencephalographic (EEG) parameter which integrates several disparate descriptors of the EEG in a single variable that correlates well with level of sedation and hypnosis 8, 9 . Hence BIS can serve as a useful tool to monitor and titrate the clinical effect of anaesthetic drugs.
Our aim was to evaluate induction doses of propofol in adult patients with end-stage renal disease, by titrating to hypnotic effect using a clinical parameter as well as the more objective assessment of BIS monitoring, and to compare the dose required with that for patients with normal renal function.
MATERIALS AND METHODS
After ethical clearance from our institutional committee and obtaining written informed consent, 27 consecutive patients with end-stage renal disease scheduled for renal allograft transplantation requiring general anaesthesia with endotracheal intubation were studied (study group=S). Twenty-seven patients of ASA status 1 and 2 with normal renal function booked for various elective surgical procedures during the same period and also requiring general anaesthesia with endotracheal intubation were taken as control (control group=C).
Patients with a known neurological disorder, those with impaired hepatic function and patients of New York Heart Association (NYHA) class IV were excluded from the study. End-stage renal disease patients received their usual anti-hypertensive medication, immunosuppression and routine haemodialysis preoperatively. Patients in both groups were premedicated with lorazepam 0.04 mg/kg and ranitidine 150 mg orally the night before and on the morning of surgery.
Patients were monitored in the operating theatre using electrocardiography (ECG), pulse oximetry, non-invasive blood pressure monitoring and BIS monitoring using the Aspect A-1000 monitor (Aspect Medical Systems; version 3.12, Natick, MA, U.S.A.). Four silver chloride electrodes were applied to the forehead with one on each outer malar bone, a third at the centre of the forehead and a fourth (ground) on the one side of the centre electrode. Impedance was kept below 2000 Ohms. The EEG signal was acquired using this frontal -Cz montage. Patients were also asked to hold a 10 ml syringe in their hand in such a way that the syringe fell when the finger grip loosened. Fentanyl 2 µg/kg was given, followed five minutes later by induction using propofol boluses of 0.2 mg /kg every 15 seconds until the patient dropped the syringe 10 . This time was recorded as the clinical end-point of hypnosis. Atracurium 0.5 mg/kg was given for muscle relaxation and patients were ventilated using 100% oxygen. Propofol injection was continued at the same rate until a mean (SD) BIS value in the range 50 (5) was achieved. This defined the objective end-point of hypnosis. Patients were intubated using an appropriate size cuffed endotracheal tube and ventilated using 100% oxygen. Heart rate, blood pressure and BIS values were recorded at baseline, at the clinical end-point of hypnosis, the objective end point of hypnosis, immediately prior to intubation and one and three minutes after intubation.
Considering the arm-brain circulation time of around 15 seconds, it is possible that propofol given at a rate of 0.2 mg/kg every 15 seconds overestimates dosage by 0.2 mg/kg. We considered that a difference in dosage between the two groups of more than 0.2 mg/kg would be significant. Power analysis indicated that 20 patients in each group were required, based on pilot data indicating a standard deviation (SD) of propofol dosage requirement of 0.4 mg/kg. Statistical analysis was performed using Student's t test and simple regression analysis. P<0.05 was considered statistically significant. Results are presented as mean (SD)
RESULTS
Mean age, weight, and body surface area were comparable ( Table 1) . As expected, patients with endstage renal disease had significantly lower haemoglobin values and higher serum creatinine values than control patients.
The mean induction dose of propofol to achieve the clinical end-point of hypnosis was 1.42 (0.24) mg/kg or 46.7 (8.9) mg/m 2 in end-stage renal disease patients. This was significantly higher (P<0.001) than control patients (0.89 (0.2) mg/kg or 33.4 (9.62) mg/m 2 ). The doses required to achieve the objective end-point of hypnosis were 2.03 (0.4) mg/kg or 67.2 (15.6) mg/m 2 ) in end-stage renal disease patients and 1.39 (0.43) mg/kg or 51.0 (15.7) mg/m 2 in control patients (P<0.001). Though there was no significant relationship between propofol dose and preoperative laboratory parameters, like serum creatinine, serum albumin and haemoglobin when analysed as separate groups, there was a significant inverse relationship to preoperative haemoglobin when data from both groups were combined (r= -0.547, P<0.01). The equation showing the relationship is y=-0.1078x+2.7394 (R 2 =0.2997). The addition of other parameters like serum creatinine or serum albumin did not improve the value of R 2 .
There was no significant difference in heart rate and mean blood pressure between the two groups at any time throughout the study period, except immediately before intubation, when mean blood pressure was significantly lower in control patients compared with end-stage renal disease patients (P<0.05). In both groups, heart rate and blood pressure was significantly decreased at the clinical and objective end-points of hypnosis as compared with base-line and increased significantly following intubation (P<0.05) ( Table 2) .
DISCUSSION
A higher dose requirement of propofol for induction of anaesthesia in end-stage renal disease patients may be due to a larger volume of distribution in these patients. Kirvella et al found a higher steady state volume of distribution of propofol in chronic renal failure patients, this being 1607 (494) litres compared with 1487 (606) litres for patients with normal function 11 . De Gasperi et al also found a larger volume of distribution of propofol at steady state in renal failure patients 2 , but these steady state conditions may not apply to acute situations like an induction dose.
Christensen JH et al 12 studied the pharmacokinetics and pharmacodynamics of thiopentone in patients undergoing renal transplantation. Mean induction doses in renal failure patients were 6.7 mg/kg (range 5.0-9.8 mg/kg) and 6.2 mg/kg (4.5-8.1 mg/kg) in control patients. The average size of the deep peripheral compartment was 2.5 times larger among patients with renal failure compared with normal renal function patients. These investigators also found that the "sleep" arterial concentration of thiopentone in renal failure patients was 31.2 µg/ml (14.7-54), which was higher (although not significantly) than normal patients in whom it was 28.9 µg/ml (17.3-40.5) . Renal failure patients appear to have some pharmacokinetic and pharmacodynamic changes due to uraemia that can lead to a higher dose requirement for anaesthetic agents.
Anaemia was another factor that could have contributed to the higher dose requirement in chronic renal failure patients. This indirectly causes a higher plasma volume and higher dose requirement. A negative correlation between the induction dose and the preoperative haemoglobin value was found in the present study but was statistically significant only when data from both groups were combined. Propofol is preferentially distributed in plasma (plasma:blood concentration 1:0.6) 13 . More of the drug will remain in the diluted higher plasma volume, thereby increasing the dose requirement in anaemia.
Cardiac output has been reported as a determinant of the initial concentration of propofol after short infusion 14 . Yushi et al identified cardiac output as an important predictive variable for the hypnotic dose of propofol during induction of anaesthesia 15 . They demonstrated that the patients with higher cardiac output required larger doses of propofol for hypnosis. For a given dose, the plasma concentration of propofol was larger in patients with low cardiac output than in patients with higher cardiac output. Uraemic patients have a hyperdynamic circulation because of co-existing anaemia 16 and this may contribute to a higher dose requirement in end-stage renal disease patients.
Various endogenous metabolites (2-hydroxy benzoyl glycine, hippuric acid and indoxy sulphate) accumulate in renal failure patients. These can act as inhibitors of protein binding, leading to reduction in the protein binding of drugs 17 . This should decrease the dose requirement, which is contrary to our findings. Vanholder et al 17 found that propranolol, clonidine, cimetidine and imipramine show an increased protein binding with progressive renal failure. All these are basic drugs, which bind preferentially to alpha 1 acid glycoprotein and levels of alpha 1 acid glycoprotein rise during renal failure.
Propofol is a weakly acidic drug that is highly bound (98-99%) to serum proteins in a non-saturable process 18, 19 . The two groups did not differ in serum protein or albumin level, but the drug is principally bound to albumin (95% bound in pure albumin solu- tion) and this may be decreased in end-stage renal disease patients. This would be expected to decrease propofol requirements. It is likely that the effect of anaemia and an associated increase in cardiac output more than offset any such effect on propofol dose requirement with resulting increase in induction dose. Another possibility may be that by some mechanism, the number of binding sites for certain drugs increases with progressive loss of renal function, thereby decreasing the available free fraction of the drug and increasing the dose requirement. However, Castela et al did not find any significant alteration in serum protein binding of propofol in chronic renal failure patients 20 . Further investigation is needed to determine reasons for a higher dose requirement in end-stage renal disease patients and to look for a correlation between plasma concentration and a measure of anaesthetic depth. We conclude that induction doses of propofol are increased for patients with end-stage renal disease compared with normal renal function patients, and we speculate that this may be related to anaemia and a hyperdynamic circulation in these patients.
